Abstract:
PROBLEM TO BE SOLVEDThe present invention is intended to provide a burdock fruit extract comprising arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of approximately 1:1.SOLUTIONA method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3 is provided, including the steps of: cutting a burdock fruit and converting arctiin which is inherent in the burdock fruit into arctigenin by enzymatic conversion by beta-glucosidase which is inherent in the burdock fruit, wherein the enzymatic conversion includes reaction at a temperature from 20° C. to 50° C. Also provided is the method further including a step of extracting an extract comprising arctigenin and arctiin by adding an organic solvent and heating to reflux.
Abstract:
A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a biodegradable substance that differs from that of the inner layer.
Abstract:
The invention provides an antibody that specifically binds to a 5′ to 3′ exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5′ to 3′ exonuclease activity of a DNA polymerase, or a fragment thereof.
Abstract:
A pharmaceutical composition for preventing or treating cystic lymphangioma comprising an agent that causes suppression of expression of amphiregulin, suppression of secretion of amphiregulin, and/or inhibition of binding of amphiregulin with an amphiregulin receptor, or an agent that causes suppression of expression of an amphiregulin receptor, suppression of activation of an amphiregulin receptor, and/or inhibition of binding of an amphiregulin receptor with amphiregulin, as an active ingredient.
Abstract:
The present invention addresses the problem of providing a material as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in subcutaneous tissue. As a solution, there is provided a dry amniotic membrane manufactured according to a specific drying process. In more detail, a raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-infrared heater (14) provided inside the processing tank (10), while performing a decompression operation where the interior of the processing tank (10) is placed in a decompressed state and irradiation of the raw amniotic membrane with microwaves from a microwave generating device (30) provided inside the processing tank (10) to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank (10) toward atmospheric pressure. By providing amniotic membrane, which has been dried by repeating the above process a plurality of times to retain its cellular and tissue structure, as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in the subcutaneous tissue, it is possible to enhance the healing effect of a skin graft.
Abstract:
A method for enabling rapid and accurate determination of the number of bacterial cells in a specimen using a PCR method includes the following steps: (1) a first PCR step of carrying out a PCR method using a nucleic acid derived from a specimen as a template and a universal primer pair for amplifying a bacterial 16S rRNA gene to obtain a first amplification product; (2) a second PCR step of carrying out a nested PCR method using a primer pair(s) for amplifying an internal sequence(s) of the sequence of the first amplification product obtained by the first PCR step to obtain a second amplification product; and (3) a bacterial number determination step of obtaining the number of bacterial cells in the specimen based on the amount of the second amplification product obtained in the second PCR step and using calibration data.
Abstract:
A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell. Threonine 18 phosphorylated p53 (pT18-p53) and threonine 68 phosphorylated CHK2 (pT68-CHK2) specific monoclonal antibodies are also disclosed.
Abstract:
A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a biodegradable substance that differs from that of the inner layer.
Abstract:
A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR′_1], [LW_1], and [ED_1] as an active ingredient.
Abstract:
The present invention is intended to provide a burdock fruit extract comprising arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of approximately 1:1.A method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of arctigenin/arctiin =0.7 to 1.3 is provided, including the steps of: cutting a burdock fruit and converting arctiin which is inherent in the burdock fruit into arctigenin by enzymatic conversion by beta-glucosidase which is inherent in the burdock fruit, wherein the enzymatic conversion includes reaction at a temperature from 20° C. to 50° C. Also provided is the method further including a step of extracting an extract comprising arctigenin and arctiin by adding an organic solvent and heating to reflux.
Abstract translation:本发明的目的在于提供一种以确定的比例含有抗坏血酸和铁蛋白的牛蒡果实提取物及其制造方法。 更具体地,本发明旨在提供一种生产牛蒡果实提取物的方法,所述牛蒡果实提取物包含重量比为约1:1的抗坏血酸和铁蛋白。 本发明提供一种以牛蒡子苷/ ar in in = = = = = = = a a a a i i i extract extract extract extract extract for for for for for for A A A A A A A A A A A A A A A A A A A A A enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic enzymatic 牛蒡果实固有的β-葡糖苷酶的转化,其中酶促转化包括在20℃至50℃的温度下的反应。还提供了该方法还包括通过以下步骤提取包含arctigenin和arctiin的提取物: 加入有机溶剂并加热回流。